Hydroxyproline Antibody from Cell Signaling Technology

Yes, the Hydroxyproline Antibody has been utilized in studies related to the Hippo pathway, particularly in the context of intrahepatic cholangiocarcinoma. For instance, in a study by Cigliano et al., the antibody was employed in immunohistochemistry to analyze the role of TAZ, a Hippo pathway effector, in tumor development in mouse models of cholangiocarcinoma (cigliano2022).

The Hydroxyproline Antibody is versatile and has been shown to react with a wide range of species, including human, mouse, rat, zebrafish, and various other mammals, birds, and even some invertebrates. This broad reactivity makes it suitable for comparative studies across different biological models.

The Hydroxyproline Antibody specifically recognizes endogenous levels of proline only when it is hydroxylated, meaning it does not react with non-hydroxylated proline. This specificity is crucial for accurately studying collagen metabolism and related processes in various tissues, particularly in the context of diseases where hydroxylation plays a significant role.

The Hydroxyproline Antibody has been cited in scientific literature for its application in immunohistochemistry, particularly in studies investigating the role of the Hippo pathway in cancer. Its use in characterizing tumor models and understanding the molecular mechanisms of cholangiocarcinogenesis highlights its relevance in cancer research.